Hutchmed announces licensing agreement with GSK for cancer therapy
HUTCHMED (China) Ltd (HKEX:13) said it has announced a licensing agreement with GSK for a Kras-EGFR-antibody conjugate cancer therapy.
Story updates
04:23:03 AM UTC
SquawkNews
HUTCHMED (China) HKEX:13 said on Thursday its unit had signed an exclusive development and licensing agreement with a subsidiary of GSK LSE:GSK to develop and commercialise its investigational cancer drug, HMPL-A830.The agreement grants the British drug maker's unit worldwide rights to develop and…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.